SeaStar Medical's required QUELIMMUNE registry study was fulfilled, clearing a specific post-approval requirement. The filing reports no sales or patient-use results, so this is a limited but favorable regulatory step.
This clears a specific study requirement tied to QUELIMMUNE's original approval. The filing reports no sales or patient-use results, so the benefit is limited to regulatory progress.
Follow SeaStar Medical Holding Corp (ICU) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ICU